Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms
Abstract The current study evaluated the effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and investigated its possible mechanisms. 124 patients were randomized to receive 25 mg empagliflozin QD, or placebo double bl...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-07395-x |
| _version_ | 1818917935905767424 |
|---|---|
| author | Lan Cheng Qianyu Fu Longhua Zhou Yuqin Fan Fenfen Liu Yuanyuan Fan Xin Zhang Weiqing Lin Xiaohe Wu |
| author_facet | Lan Cheng Qianyu Fu Longhua Zhou Yuqin Fan Fenfen Liu Yuanyuan Fan Xin Zhang Weiqing Lin Xiaohe Wu |
| author_sort | Lan Cheng |
| collection | DOAJ |
| description | Abstract The current study evaluated the effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and investigated its possible mechanisms. 124 patients were randomized to receive 25 mg empagliflozin QD, or placebo double blind for 12 weeks. Patients underwent 24-h ABPM. Endothelial function and arterial stiffness were also measured prior to randomization and at week 12. At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP was − 8.14 mmHg (95% CI − 10.32, − 3.96, P = 0.005). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP was − 5.27 mmHg (95% CI − 8.19, − 1.35, P < 0.001). Changes in office BP were consistent with ABPM. Empagliflozin was well tolerated. Empagliflozin was associated with significant and clinically meaningful reductions in BP versus placebo in Chinese elderly patients with type 2 diabetes and hypertension. The underlying mechanisms possiblely at least in part were the improvements of endothelial function and arterial stiffness associated with empagliflozin. Registration number: ChiCTR2100054678, Registration date: December 23, 2021. |
| first_indexed | 2024-12-20T00:41:59Z |
| format | Article |
| id | doaj.art-9085fc8465d3449ba4fa6f1c47fb8b70 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-20T00:41:59Z |
| publishDate | 2022-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-9085fc8465d3449ba4fa6f1c47fb8b702022-12-21T19:59:31ZengNature PortfolioScientific Reports2045-23222022-03-011211810.1038/s41598-022-07395-xEffect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanismsLan Cheng0Qianyu Fu1Longhua Zhou2Yuqin Fan3Fenfen Liu4Yuanyuan Fan5Xin Zhang6Weiqing Lin7Xiaohe Wu8Jiangxi Provincial People’s HospitalJiangxi Provincial People’s HospitalJiangxi Provincial People’s HospitalJiangxi Provincial People’s HospitalJiangxi Provincial People’s HospitalJiangxi Provincial People’s HospitalJiangxi Provincial People’s HospitalJiangxi Provincial People’s HospitalJiangxi Provincial People’s HospitalAbstract The current study evaluated the effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and investigated its possible mechanisms. 124 patients were randomized to receive 25 mg empagliflozin QD, or placebo double blind for 12 weeks. Patients underwent 24-h ABPM. Endothelial function and arterial stiffness were also measured prior to randomization and at week 12. At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP was − 8.14 mmHg (95% CI − 10.32, − 3.96, P = 0.005). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP was − 5.27 mmHg (95% CI − 8.19, − 1.35, P < 0.001). Changes in office BP were consistent with ABPM. Empagliflozin was well tolerated. Empagliflozin was associated with significant and clinically meaningful reductions in BP versus placebo in Chinese elderly patients with type 2 diabetes and hypertension. The underlying mechanisms possiblely at least in part were the improvements of endothelial function and arterial stiffness associated with empagliflozin. Registration number: ChiCTR2100054678, Registration date: December 23, 2021.https://doi.org/10.1038/s41598-022-07395-x |
| spellingShingle | Lan Cheng Qianyu Fu Longhua Zhou Yuqin Fan Fenfen Liu Yuanyuan Fan Xin Zhang Weiqing Lin Xiaohe Wu Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms Scientific Reports |
| title | Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms |
| title_full | Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms |
| title_fullStr | Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms |
| title_full_unstemmed | Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms |
| title_short | Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms |
| title_sort | effect of sglt 2 inhibitor empagliflozin on blood pressure reduction in chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms |
| url | https://doi.org/10.1038/s41598-022-07395-x |
| work_keys_str_mv | AT lancheng effectofsglt2inhibitorempagliflozinonbloodpressurereductioninchineseelderlyhypertensionpatientswithtype2diabetesanditspossiblemechanisms AT qianyufu effectofsglt2inhibitorempagliflozinonbloodpressurereductioninchineseelderlyhypertensionpatientswithtype2diabetesanditspossiblemechanisms AT longhuazhou effectofsglt2inhibitorempagliflozinonbloodpressurereductioninchineseelderlyhypertensionpatientswithtype2diabetesanditspossiblemechanisms AT yuqinfan effectofsglt2inhibitorempagliflozinonbloodpressurereductioninchineseelderlyhypertensionpatientswithtype2diabetesanditspossiblemechanisms AT fenfenliu effectofsglt2inhibitorempagliflozinonbloodpressurereductioninchineseelderlyhypertensionpatientswithtype2diabetesanditspossiblemechanisms AT yuanyuanfan effectofsglt2inhibitorempagliflozinonbloodpressurereductioninchineseelderlyhypertensionpatientswithtype2diabetesanditspossiblemechanisms AT xinzhang effectofsglt2inhibitorempagliflozinonbloodpressurereductioninchineseelderlyhypertensionpatientswithtype2diabetesanditspossiblemechanisms AT weiqinglin effectofsglt2inhibitorempagliflozinonbloodpressurereductioninchineseelderlyhypertensionpatientswithtype2diabetesanditspossiblemechanisms AT xiaohewu effectofsglt2inhibitorempagliflozinonbloodpressurereductioninchineseelderlyhypertensionpatientswithtype2diabetesanditspossiblemechanisms |